gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PRPOHealthcareLab Analytical Instruments

Precipio, Inc. Common Stock (PRPO)

$19.57+5.10%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$19.57▼ 2.49% in range
Nov 4, 2025Low $17.79 · High $32.37Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Precipio closed at $19.57 on Nov 4, up 5.10%, 39.5% below its 52-week closing high. Volume of 8.1K shares was 0.21× its 20-day average (below normal).

Split-adjusted performance: -16.5% over one month, -34.7% over six months, -2.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $7.02M, up 24.7% from a year earlier, with a net margin of -3.1%.

Short interest was 58.9K shares at the Oct 15 settlement, down 14.2% from the prior report (3.6% of float, 1.5 days to cover).

Market cap$35.0M1.8M shares
Revenue · quarter$7.0M+24.7% YoY
Diluted EPS$-0.12−340.0% YoY
P/E · TTM—P/S 1.3×
Net margin-3.1%Gross 44.7%
Dividend yieldNone
52-week range17.79 – 32.37−39.5% from high
Volume8.1K0.21× 20-day avg
Volatility · 60d55.3%Annualised
Short % of float3.6%1.5 days to cover
Net cash$1.9MCash $3.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +4.8%1M −16.5%3M −16.6%6M −34.7%YTD −14.8%1Y −2.0%3Y +146.9%5Y −58.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum10
Revenue growth90
Net margin71
Value (low P/E)—
Size19

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →
Shares short58.9K−14.2% vs prior
Days to cover1.5Settled Oct 15
% of float3.6%
Short vol. 10d39.7%of daily volume

Closest peers by size in Lab Analytical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PRPOPrecipio$19.57+5.10%−34.7%+24.7%−3.1%—$35.0M
RPIDRapid Micro Biosystems$0.6814−1.53%−73.1%+10.9%−160.5%—$34.2MCompare
EYPTEyePoint$0.3950−1.23%−97.0%−90.5%−18633.1%—$34.1MCompare
HBIOHarvard Bioscience$8.61−0.69%+18.9%+11.1%−12.8%—$39.2MCompare
BNGOBionano Genomics$1.19−0.83%−6.3%+21.4%−90.8%—$16.6MCompare
SEERSeer$1.70−1.73%−10.1%−23.4%−544.8%—$94.1MCompare
ASTCAstrotech Corporation (DE)$4.51−7.20%+62.2%−42.7%−2592.1%—$9.5MCompare
QTRXQuanterix$3.04+3.40%−7.6%+34.4%−148.7%—$143.8MCompare
NAUTNautilus Biotechnolgy$2.29−2.55%−22.1%—−6682.1%—$291.7MCompare

News about Precipio

All news →
Precipio Announces Q3-2026 Shareholder Update CallGlobeNewswire Inc. · Oct 28, 2026▲ PositivePRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?Zacks Investment Research · Sep 22, 2026NeutralPrecipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders MeetingGlobeNewswire Inc. · Jun 12, 2026▼ NegativePrecipio to Present at the Planet MicroCap Las VegasGlobeNewswire Inc. · Jun 11, 2026▲ PositivePrecipio Announces Q1 2026 Financial ResultsGlobeNewswire Inc. · May 14, 2026Neutral

Quick answers

What does Precipio do?
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation.
What is PRPO's market cap?
$35.03M, based on the Nov 4 close of $19.57.
Does Precipio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PRPO is sold short?
58.9K shares, 3.6% of float, as of Oct 15, 2026.
What sector is PRPO in?
Healthcare, in the Lab Analytical Instruments industry.

About Precipio

Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.

HQ: New Haven, CT71 employeesListed Jul 18, 2000precipiodx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology